Johanna Röstin
Consejero General en VIVESTO AB .
Perfil
Johanna Röstin currently works at Vivesto AB, as Chief Regulatory Officer.
Ms. Röstin also formerly worked at OxThera AB, as Director-CMC, Program Management & Regulatory and Swedish Orphan Biovitrum AB, as Manager-Global Senior Regulatory Affairs.
Ms. Röstin received her graduate degree from Royal Institute of Technology.
Cargos activos de Johanna Röstin
| Empresas | Cargo | Inicio |
|---|---|---|
| VIVESTO AB | Consejero General | 01/10/2021 |
Antiguos cargos conocidos de Johanna Röstin.
| Empresas | Cargo | Fin |
|---|---|---|
| SWEDISH ORPHAN BIOVITRUM AB | Consejero General | - |
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Consejero General | - |
Formación de Johanna Röstin.
| Royal Institute of Technology | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| VIVESTO AB | Health Technology |
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| Empresas privadas | 1 |
|---|---|
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Health Technology |
- Bolsa de valores
- Insiders
- Johanna Röstin
